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Abstract
Background: Isolated limb infusion (ILI), introduced in 1992, is a technique used to 
deliver regional chemotherapy to treat advanced melanoma confined to a limb. Ad-
justing melphalan dose according to ideal body weight (IBW) has been proposed as 
a method of decreasing limb toxicity without compromising outcome. The current 
study analyzed this proposed dose adjustment.
Methods: We reviewed 99 consecutive patients with lower extremity melanomas 
treated by ILI at our institution between May 1998 and February 2009. Toxicity and 
outcomes were tested for correlation with differences between administered dose 
and calculated adjusted dose, both in mg and mg/l, and with differences between 
actual limb volume and calculated adjusted limb volume.
Results: The median actual body weight was 71 kg, whereas the calculated median 
IBW was 57 kg (p < 0.001). Median administered melphalan dose was 7.7 mg/l. The 
median calculated adjusted dose was 6.5 mg/l (range 3.2–9.3 mg/l, p < 0.001). None 
of the three aforementioned parameters correlated with either Wieberdink toxicity 
grade or outcome. BMI did not correlate with toxicity either.  Interestingly, a higher 
total melphalan dose did not only correlate with higher toxicity, but also with a lower 
response rate.
Conclusions: Adjusting the melphalan dose for IBW does not appear to reduce tox-
icity following ILI for melanoma. The effect on outcome remains uncertain. More re-
search is needed to optimize melphalan concentrations in individual patients during 




Isolated limb infusion (ILI) with cytotoxic drugs was developed by Thompson et al. in 
the early 1990s at Melanoma Institute Australia (MIA, formerly known as the Sydney 
Melanoma Unit) as a simple, minimally invasive alternative to isolated limb perfu-
sion (ILP) to treat advanced and recurrent melanoma confined to a limb.1,2 Since its 
introduction, only a few studies have examined the pharmacokinetics and pharma-
codynamics of melphalan during ILI. Therefore, little is known about optimizing the 
therapeutic index of melphalan during the procedure.3–6
Currently, melphalan dosing for ILI is based on measured limb volume, as it is for 
conventional ILP. Since the introduction of the ILI technique, the melphalan dosage 
has varied from 5 to 10 mg/l of tissue; currently, 7.5 mg/l is generally considered 
to be the optimal dose. Despite research investigating the influence of the infused 
melphalan dose in mg/l on toxicity and outcome, its relationship with toxicity and 
outcome remains unclear.7–9 Melphalan concentration levels, measured in limb blood 
samples during the ILI procedure, have been shown to be significant predictors of 
Wieberdink grade III and grade IV toxicity.8 However, melphalan concentration levels 
are quite variable in individual patients, and the factors that determine melphalan 
concentration levels are not fully understood.10,11 
In an attempt to optimize the dosing of melphalan, a group at the Duke University 
Medical Center proposed adjusting melphalan dosage according to the ideal body 
weight (IBW) of the patient.12 This suggested adjustment was based primarily on the 
observation that the strongest predictor of toxicity in patients undergoing conven-
tional ILP was the ratio of estimated limb volume (Vesti) to steady-state limb drug 
volume of distribution (Vss).10,11 Hypothetically, patients with a weight greater than 
their IBW are likely to have a high Vesti/Vss because melphalan uptake is lower in fat-
ty tissue compared with muscle.13 It was proposed that adjusting the melphalan dose 
according to IBW would decrease this ratio and therefore minimize the risk of over-
dosing and prevent unnecessary limb toxicity.8 In one recent study it was reported 
that this dose adjustment did indeed decrease limb toxicity without compromising 
response rates.12 However, two other studies showed that while dose adjustments 
according to IBW decreased toxicity it was at the expense of a lower partial response 
(PR), while the complete response (CR) rates remained unchanged.9,11 The aim of 
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the present study was to analyze whether adjusting melphalan dosage according to 
IBW would indeed be an effective method of reducing toxicity without compromising 
outcome in the patients treated with ILI in our institution.
Patients and methods
From November 1992 to February 2009, 339 ILI procedures for lower extremity mel-
anoma were performed in 232 patients at MIA, Sydney, Australia. Patients were ei-
ther treated with a single ILI procedure (n = 142), two ILIs (n = 77), three ILIs (n = 9), 
or four ILIs (n = 4). In May 1998 the drug circulation time was increased from 20 to 
30 min, when it became apparent that drug uptake was not complete after 20 min. 
To eliminate any bias caused by this change in drug circulation time and to increase 
the applicability of this study to currently treated patients, only patients treated af-
ter May 1, 1998 were included in this study. We used only the results of the first ILI 
treatment of every patient. 
Using these inclusion criteria, we identified 113 patients from our prospectively col-
lected database. Of those patients, 13 were excluded from the analysis because their 
weight and/or or height, necessary to calculate their IBW, was not recorded at time 
of the ILI procedure or was unable to be located. Furthermore, one ILI procedure 
was performed on compassionate grounds, at the request of a terminally ill patient. 
This patient, as expected, died 7 days after the procedure and was not included in 
the analysis because post-ILI toxicity was unable to be assessed. This left a final study 
cohort of 99 patients. 
The ILI procedures were performed as described in detail previously.14 The planned 
drug circulation time was 30 min. A melphalan dose of 7.5 mg/l of infused tissue 
was usually administered, with a maximum dose of 100 mg for large tissue volumes. 
For practical purposes the melphalan dose was rounded up or rounded down to an 
easily measured integer, based on clinical judgment primarily relating to the volume 
of tumor in the limb. Actinomycin D was also used, in a dosage of 75 µg/l of infused 
tissue with a minimum of 200 µg and a maximum of 500 µg. It was used in addition 
to melphalan because of the remarkably good response rates achieved without any 
apparent increase in toxicity when this drug combination had been administered in 
conventional ILP at MIA.15–17 For every patient, preoperative limb volume measure-
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ments were made using a water-displacement method, as first described by Wieber-
dink et al.18 
Responses were assessed according to standard World Health Organization criteria.19 
These define CR as the disappearance of all measurable disease, determined by two 
observations not less than 4 weeks apart, and a PR as a decrease of 50% or more in 
total tumor size determined by two observations not less than 4 weeks apart and no 
appearance of new lesions or progression of any lesion. In this study, patients who 
did not have a CR or PR were classified together as ‘no response.’ It was possible to 
evaluate the responses of all 99 patients included in the final study cohort. Postop-
erative limb toxicity, systemic toxicity, and serum creatine phosphokinase (CPK) were 
assessed daily. Limb toxicity was graded using the scale proposed by Wieberdink et 
al.18 Because of the strong relationship between a raised CPK and increased limb tox-
icity after ILI, all patients who had a CPK level exceeding 1,000 IU/l postoperatively 
or who developed Wieberdink grade III toxicity or higher were treated with systemic 
corticosteroids until their CPK levels had fallen below 1,000 IU/l and their toxicity had 
dropped below grade III.8,15,16 
The IBW (in kg) was calculated using the standard method; IBW for males was calcu-
lated using the formula 50 + 2.3 x (patient height in inches - 60) and IBW for females 
was calculated using the formula 45.5 + 2.3 x (patient height in inches - 60).20 The 
‘corrected’ melphalan dose for each patient was calculated according to the formula 
proposed by Beasley et al.: 7.5 mg/l x measured volume of extremity (l) x IBW (kg) 
÷ actual body weight (BW in kg) = corrected melphalan dose in milligrams (mg).12 
Similarly, the corrected melphalan dose in mg/l was calculated by: 7.5 mg/l x IBW 
(kg) ÷ BW (kg). 
The following statistical approach was used to test whether adjusting melphalan dose 
according to IBW reduces toxicity without compromising outcome. Patients who re-
ceived an actual melphalan dose larger than their calculated corrected melphalan 
dose in either mg or mg/l are theoretically at higher risk for toxicity than patients 
who received an actual melphalan dose close to or lower than their calculated cor-
rected melphalan dose. Therefore, the difference between the actual administered 
melphalan dose and corrected melphalan dose in both mg and mg/l (∆ melphalan 
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dose), was tested for correlation with toxicity and outcome. The correction of mel-
phalan dose according to IBW can also be interpreted as a correction of the volume 
of the infused limb. Therefore, we also tested the difference between measured limb 
volume and the corrected limb volume (∆ limb volume) for correlation with toxicity 
and outcome.
The correlation between variables was tested using Spearman’s rank correlation co-
efficient (ρ). A significant difference was assumed for a probability value of < 0.05. 
The software package SPSS 17.0 for Windows (SPSS, Inc., Chicago, IL) was used for 
statistical analyzes.
Results
Patient and Tumor Characteristics
Of the 99 patients 36 were male and 63 female; their ages ranged from 29 to 93 
years (median 74 years). The majority of the patients (77%) had MD Anderson stage 
IIIa disease (in-transit metastases) or IIIab disease (in-transit metastases with nodal 
involvement), 19% had stage IV disease (distant metastases).21,22 In our patient group 
the median BMI (IQR) was 25 kg/m2 (22–28 kg/m2). The median actual body weight 
(IQR) was 71 kg (60–82 kg) and was significantly greater than the median  calculated 
IBW (IQR), which was 57 kg (52–68 kg, p < 0.001). Of the 99 patients, 14 weighed less 
than their calculated IBW. The median measured limb volume (IQR) was 6.0 l (4.3–7.3 
l), and the median calculated adjusted limb volume (IQR) was 4.7 l (3.7–6.1 l), again 
a significant difference (p < 0.001). Wieberdink toxicity grade I or II occurred in 62 of 
the 99 patients postoperatively, 35 patients experienced grade III toxicity, and two 
patients experienced Wieberdink toxicity grade IV. No grade V toxicity was seen. The 
overall response rate was 80%. A CR occurred in 36 patients and a PR in 43 patients. 
These and other patient and tumor characteristics are documented in Table 1.
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Table 1: Patient characteristics
Variable
ILI procedures 99
Age, years (range) 74 (29-93)
Sex (male/female) 36/63
Weight, kg (IQR) 71 (60-82)
BMI, kg/m2 (IQR) 25 (22-28)
IBW, kg (IQR) 57 (52-68)
Limb volume, l (IQR) 6.0 (4.3-7.3) 
Corrected limb volume, l (IQR) 4.7 (3.7-6.1)
MD Anderson stage 
   I 1
   II 2
   IIIa 41
   IIIab 36
   IV 19
Location in the limb 
   Thigh 27
   Leg 67
   Foot 5
Depth of infiltration 
   Cutaneous 32
   Subcutaneous 21
   Cutaneous and subcutaneous 42
   Into fascia 4
Wieberdink toxicity
    I/II 
    III/IV 
62
37 
Peak Serum CPK, IU/l  (IQR) 979 (185-3000)
Post-op day of serum CPK peak (IQR) 5 (4-6)
Complete response (no. of patients) 36
Partial response (no. of patients) 43
IQR, interquartile range; kg, kilograms; BMI, body mass index; kg/m2, kilograms per square meter; IBW, 
ideal body weight; CPK, creatine phosphokinase; IU/l, units per litre.
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Melphalan Dosing
Intraoperative variables recorded during the ILI treatment are shown in Table 2. The 
median actual infused melphalan dose was 7.7 mg/l (IQR: 7.4–8.0), and the median 
calculated corrected dose was 6.5 mg/l (IQR: 5.6–7.1); this difference of 16% was 
statistically significant (p < 0.001). The median peak melphalan concentration was 
22.6 µg/ml (IQR: 18.7-28.8). The median final melphalan concentration level was 9.8 
µg/ml (IQR: 8.1-12.7). 
Correlations
The actual melphalan dose in mg/l did not correlate with either outcome or toxicity 
after treatment with ILI (Table 3). However, the total melphalan dose in mg correlat-
ed with both outcome and toxicity in a way that higher infused melphalan doses in 
mg correlated with lower response rates (p = 0.041; Spearman ρ = - 0.206) and higher 
toxicity grades (p = 0.005; Spearman ρ = 0.279). BMI was not a predictor for toxicity 
or outcome. The intraoperative measured melphalan concentrations correlated with 
toxicity, but not with outcome. 
The ∆ melphalan dose in mg/l and in mg, and ∆ limb volume, did not correlate with 
toxicity or outcome. These and other correlations are shown in Table 3. Figure 1 
shows in a boxplot the relationships between total melphalan dose, BMI, and limb 
volume with Wieberdink toxicity grades and response.
Table 2: Intraoperative variables
Variable Median (IQR)
Infused melphalan dose (mg/l) 7.7 (7.4-8.0)
Adjusted melphalan dose (mg/l) 6.5 (5.6-7.1)
Peak melphalan concentration (µg/ml) 22.6 (18.7-28.8)
Final melphalan concentration (µg/ml) 9.8 (8.1-12.7)
Melphalan concentration AUC (µg/ml) 103 (83-123)
Drug exposure time (min) 31 (30-32)
Tourniquet time (min) 65 (59-71)
IQR, interquartile range; mg/l, milligrams per litre; µg/ml, micrograms per millilitre; min, minutes.
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*Volume×IBW/BW, **7.5mg/l×IBW/BW, †V×7.5mg/l×IBW/BW. Mg, milligram; l, litre; µg/ml, microgram per 
millilitre; AUC, area under the curve; BMI, body mass index; IBW, ideal body weight. 
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Figure 1: Boxplots showing the relation between Wieberdink toxicity (B, D, F) and response rate (A, C, E) 
and melphalan dose in mg, limb volume in litres and BMI. 





ILI with cytotoxic drugs was developed as an alternative to the more complex and 
invasive conventional ILP technique.1,2 Despite its minimally invasive character, post-
operative limb toxicity following ILI is comparable to that seen after ILP and is at-
tributed principally to the effects of the melphalan that is administered during the 
procedure.8,9 In an ILI animal model, increasing the infused melphalan concentra-
tion level above 25 µg/ml did not further increase response rates.21,23 This suggests 
that increasing the melphalan dose above a certain threshold only increases toxicity 
without improving response. It would therefore seem logical to keep the dose as 
low as possible to achieve a maximal response, which will in turn minimize toxicity. 
However, the best way to select the optimal melphalan dose for ILI remains a topic 
for debate. 
Currently melphalan dosing for ILI is based on measured limb volume. In this study, 
water displacement was used to estimate limb volume. This method is subject to a 
margin of error, which in turn causes a margin of error in the administered drug dose. 
However, the water displacement method is widely used for both ILI and ILP since 
alternative methods of estimating limb volume have similar margins of error. A more 
precise method of measuring limb volume would be valuable in any future study. 
A proposed method to further lower toxicity is the adjustment of melphalan dose to 
IBW.11 This method originates from the fact that melphalan uptake is lower in fatty 
tissue than it is in muscle. Overweight patients have a lower muscle/fat ratio com-
pared with patients with a weight closer to their IBW; this might cause the muscle 
compartment of these overweight patients to be relatively overdosed when using 
limb volume to calculate the melphalan dose.13 In this study we further analyzed this 
hypothesis.
We found no correlation between ∆ melphalan dose in either mg or mg/l and Wie-
berdink toxicity. This is an outcome that is the opposite of results found in earlier 
reports, in which adjusting the melphalan dose according to IBW did appear to lower 
the observed toxicity grades.7,9,11,12 An explanation for this discrepancy could be the 
smaller reduction of melphalan dose that would have resulted from correction to 
IBW in our patient population. In the study conducted by McMahon et al. the median 
reduction of the melphalan dose was 21.7%.11 In our study, the theoretical medi-
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an melphalan reduction was 15.6%. Although this is still a significant reduction, our 
patient population may not have been ‘heavy’ enough to obtain benefit from dose 
reduction according to IBW.
Another possible explanation for the discrepancy in the results could be the fact 
that although the standard melphalan dosage was 7.5 mg/l, the surgeon often ad-
justed the dose slightly based on clinical judgment, particularly the volume of tumor 
in the limb.24,25 Although, the adjustments in melphalan dose were normally small, 
and more often resulted in a higher melphalan dose than a lower dose (56% of our 
patients received a dose > 7.5 mg/l and 29% received a dose < 7.5 mg/l), they may 
have had an effect on toxicity and might have contributed to our failure to demon-
strate a correlation between dose adjustment and toxicity. Finally, differences in the 
procedure protocol and the related intraoperative variables may also have caused 
a different toxicity profile for our patients compared with patients in other studies. 
It is interesting to note that there was a positive correlation between melphalan dose 
in mg and toxicity while there was a negative correlation with outcome. Toxicity in-
creased with higher melphalan doses, while response rates decreased with these 
higher melphalan doses. We are not the first to note this unexpected outcome: Bea-
sley et al. made a similar observation, reporting increasing melphalan dose in mg as a 
risk factor for toxicity and an association between smaller limb volume (treated with 
a smaller melphalan dose in mg) with a better overall response.9 This phenomenon 
is not clearly understood. Melphalan dose in mg is directly related to the measured 
limb volume. The measured limb volume depends on the location of the tumor on 
the limb, which determines the level of placement of the tourniquet, and the height 
and weight of the patient. One might therefore expect that adjustment of melphalan 
dose to IBW should have an effect on toxicity. The ratio between body weight and 
IBW alone might not adequately assess the relative volume of fat in the limb, a hy-
pothesis supported by the finding that limb volume and toxicity were significantly 
correlated, while no correlation was found between BMI and toxicity. 
What must be understood is that administering 30 mg of melphalan to 4l of limb 
volume in patient A is not necessarily the same as administering 45 mg of melphalan 
to 6l of limb volume to patient B, although both patients received 7.5 mg/l. This 
55
Chapter 2
is important because current methods of determining melphalan dosage are based 
on limb volume only. The important shortcomings in the current method of esti-
mating melphalan dosage is underlined by our finding that there was no correlation 
between melphalan dose in mg/l and toxicity, whereas the absolute melphalan dose 
(i.e., total mg administered) was positively correlated with toxicity. Based on our re-
sults, patient B would be more likely to develop greater toxicity, even when the two 
patients had the same BMI (or IBW-to-BW ratio).
The complex interactions between melphalan dosage, limb volume measurement, 
toxicity, and response during isolated regional chemotherapy were recognized and 
discussed in considerable detail 30 years ago by Wieberdink et al.18 They pointed 
out that regional volumes as a percentage of body weight showed a ±30% variability 
from the mean, resulting in similarly wide variability of the dose of cytotoxic drug 
used. They also pointed out that the volume of the lower limb is relatively under-
estimated and may contribute to the lack of correlation between melphalan dose 
in mg/l and toxicity. It has long been known that to achieve satisfactory response 
rates for upper limb ILP with melphalan, a higher dose in mg/l is required (normally 
13 mg/l), compared with a standard dose of 10 mg/l for the lower limb. Wieberdink 
et al. further pointed out that toxicity may be influenced not only by cytotoxic drug 
concentration, but also by the impaired tolerance of normal tissues to the adminis-
tered drug when tissue flow rates are low.18 Certainly, lower flow rates are normally 
achieved when upper limb ILP is performed compared with flow rates for lower limb 
ILP, and even lower flow rates are achieved during ILI.
Limb volume may also play an important role in the negative correlation between 
the total melphalan dose and response rates. Larger limbs have a larger volume in 
which the drug will have to distribute after infusion. Therefore, it may take more time 
to fully circulate the drug, which could lead to a diminished ‘first-pass’ effect, with 
lower melphalan concentrations ultimately reaching the tumor deposits because of 
the short melphalan elimination halflife.26 However, this cannot fully explain why pa-
tients who received a larger quantity of melphalan had lower response rates because 
limb volume itself was not correlated to response (p = 0.10). The current study does 
not provide us with a clear answer as to what causes the lower response rates in pa-
tients with larger infused limb volumes. However, there must be concern that further 
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lowering the melphalan dose in those patients could have an unfavorable effect on 
outcome.
A correlation between ∆ melphalan dose and outcome to detect a negative effect of 
dose adjustment on outcome could not be demonstrated because we did not actu-
ally adjust the melphalan dose administered to our patients. However, we did not 
detect a beneficial effect of a higher weight than the IBW on outcome. This confirms 
the current opinion that increasing the melphalan dose is not likely to further in-
crease response rates.
There have been three other studies published that evaluated the effect of adjusting 
melphalan dose to IBW and its effect on toxicity and outcome.9,11,12 All three showed 
a significant reduction in toxicity, while CR rates were not affected. However, two of 
these studies showed a reduction in the PR rate.9,11 The multi-institutional study of 
Beasley et al. showed a PR rate of 11% in the ‘corrected’ group,9 whereas it was 48% 
in the ‘uncorrected’ group, and in the relatively small study by McMahon et al. the 
PR rate was 27% in the uncorrected group and 7% in the corrected group.11 Further-
more, the disease progressed in 48% of the patients in the ‘corrected’ group com-
pared with 18% in the ‘uncorrected’ group. Although one might argue that CRs are 
clinically most important, the reductions in PR due to a lowering of the melphalan 
administered are clinically relevant since a PR and even stable disease following an 
ILI do improve the quality of life in most patients.
In conclusion, this study shows that adjusting melphalan dose according to IBW most 
likely would not significantly decrease the toxicity associated with ILI in our patient 
population. In seeming contrast with this, a higher total administered melphalan dose 
was positively correlated with toxicity. Patients with higher infused limb volumes ex-
perienced more toxicity without a correlation with a higher BMI. The study indicates 
that much is still unknown about the effect of adjustments in the melphalan dose 
with regard to toxicity and outcome. For a better understanding of these effects, 
more research is needed; this should focus on optimizing the melphalan concentra-
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